The ₹1 lakh health test that's becoming the new status symbol. But should it?

Walk into a few wellness clinics in South Bombay this month and there is a new accessory making the rounds: sandwiched between the Erewhon tote bag and the Oura ring. It is a 25-page report, perfectly bound, with the words “Mira One” embossed in gold.

If you have not yet been handed one by a friend at brunch, give it a fortnight. Across Pune, Mumbai, and Delhi, India’s wellness-curious upper middle class has fallen in love with the genome.

Mira One is a test from PreventiveHealth.ai, built in partnership with GenePath Diagnostics, one of India's most established genomic labs. It bundles three things into a single ₹1 lakh investigation: a comprehensive blood-marker panel, a pharmacogenomic screen that maps how your body metabolises 200-plus commonly prescribed medications, and a whole-genome sequencing that reads the protein-coding parts of your DNA. You do it once. Your genome does not change. The report, whatever it says, you carry forward for the rest of your life.

It is, structurally, the opposite of the wellness industry’s usual offer of repeat purchases and subscription tiers. You pay one large bill, and then you stop being charged.

The status part is harder to ignore. “I have done Mira One” has become, in the past two months, the kind of dinner-party throwaway that used to be reserved for “I have done Vipassana” or “I have just come back from Bhutan.” Some founders in BKC have even reportedly bought it for their leadership teams as a gesture of founder care.

None of which tells you whether it is actually worth doing.

To find out, we spoke to the team that built it.

Dr. Swapna Gadgil Gambhir, a Functional Medicine (Lifestyle Medicine) expert working within NHS Scotland and an advisor to PreventiveHealth.ai, describes Mira One as a powerful tool for long-term, personalised patient care. “In functional medicine, we want to understand the why, not just the what,” she said. “An elevated marker tells you something is off. The genomic layer helps us determine whether the driver is lifestyle, medication response, or inherited predisposition. The treatment approach can look completely different depending on the underlying cause, and that deeper insight is what makes truly personalised care possible.

Dr Sneha Raje, the company’s clinical dietitian with 20 years of experience across metabolic health and sports nutrition, sees the test as the missing layer in personalised eating. “For years, my nutrition plans have been built on blood markers, lifestyle history, and trial,” she said. “A Mira One report adds a layer of precision nutrition as the third dimension… Your body’s actual response patterns at the genomic level. I have rewritten plans for several patients in the past six months based purely on what the report told me about their metabolism, their nutrient absorption, their cardiovascular variants. The plans that follow are personalised with evidence.”

There are, naturally, sceptics. A senior internal-medicine physician at a Mumbai medical college, who asked not to be named, made the most honest case against the test: "The report is excellent. The risk is that patients walk into clinics expecting their doctors to have read it. Most Indian doctors have not yet been trained to read sixty pages of genomic data. That gap closes over time, but right now it is real."

PreventiveHealth.ai addresses this in part by including a one-hour clinical interpretation call with a physician on their panel as part of every Mira One report. Whether the broader Indian medical establishment catches up to genomic literacy at the pace of patient demand is, for now, an open question.

So is it a flex? Of course it is. There is no version of spending ₹1 lakh on a single health test that is not, in part, a flex. But the more interesting question is whether it is also a smart thing to do — and the answer, for any reasonably affluent Indian over the age of 35 with a family history of anything, appears to be yes.

The Bandra brunch crowd has, we suspect, accidentally stumbled onto something genuinely useful. Which, we will admit, is not what we expected to be writing when we started this piece.

Mira One is an integrated diagnostic that brings blood biomarkers, pharmacogenomics, and whole genome sequencing together into a single easy-to-read report. This helps your doctor understand not only what may be going wrong but also how your body is likely to respond to specific medications. It only needs to be done once. More info here.